Polaris Capital Q1 2026: Deep Value, Spread Worldwide

If Greenhaven Associates shows what deep value looks like when it is poured into a handful of names, Polaris Capital Management shows the opposite expression of the same instinct: value spread thin and wide. The Boston-based global manager's first-quarter 2026 13F covers $1.22 billion across 84 positions, and its largest holding commands barely 7% of the book. This is contrarian investing by breadth — a diversified net cast across out-of-favor businesses in the United States, Latin America, and Europe, with no single bet large enough to sink the portfolio on its own.

The top of the book is a tour of unloved corners of the market. Popular Inc, the dominant bank in Puerto Rico, is the largest position at 7.12% ($87.0 million). Behind it sit two Irish-domiciled names — Jazz Pharmaceuticals at 6.42% and the industrial-gas giant Linde at 5.05% — followed by United Therapeutics at 4.69% and the packaging combination Smurfit WestRock at 4.46%. It is a deliberately international, deliberately cheap collection of franchises.

Where the conviction sits

Polaris was a net trimmer at the top in Q1 2026, shaving its largest positions rather than adding to them. Popular Inc was cut about 5% in share terms, Linde roughly 7%, United Therapeutics about 7%, and Smurfit WestRock around 6% — modest reductions that read as profit-taking and rebalancing rather than a change of heart. The clearest positive signal came lower in the book: Lantheus Holdings, the radiopharmaceutical maker, where Polaris lifted its stake about 15% to a 3.83% weight. When a manager is trimming its anchors and adding to a mid-sized position, that mid-sized name is usually where the freshest conviction lies.

The most consequential new idea was Eastman Chemical, which entered the portfolio as a brand-new 2.94% position. A cyclical specialty-chemicals maker trading at a value multiple is squarely in Polaris's wheelhouse, and a fresh top-ten entry is the kind of move that tells you where the firm is putting new capital to work. Around it, the book leans into classic value sectors: energy through Marathon Petroleum (3.11%), healthcare through CVS Health (3.04%) and Gilead Sciences, distribution through Arrow Electronics (3.36%), and financials through JPMorgan.

Diversification as a discipline

The concentration profile is the defining contrast with most of the high-conviction managers that dominate 13F coverage. Polaris's top ten holdings account for only about 44% of assets — meaning the long tail of roughly 74 remaining positions carries more than half the portfolio. No single name can dictate the fund's fate.

That breadth is a feature of the strategy, not an accident. Polaris runs a global value mandate in which dozens of small-to-mid-sized positions, each bought at a discount to intrinsic value, are expected to rerate on their own timelines. The approach trades the explosive upside of a concentrated bet for resilience: a blown thesis in any one name is a rounding error, and the portfolio's return is the aggregate of many independent value realizations. For investors using 13F data, Polaris is a useful reminder that "active, discretionary money" does not always mean "concentrated" — disciplined diversification is itself an active choice.

An AUM story worth noting

The reported 13F value was essentially flat quarter over quarter, ticking up 1.4% from $1.21 billion to $1.22 billion as the position count eased from 89 to 84. But the longer arc is more telling: Polaris's reported U.S. assets have declined from above $2.0 billion in 2024 to the current $1.22 billion.

That drawdown — a roughly 40% decline in reported value over six quarters — is the kind of detail an honest read of a 13F should surface rather than gloss over. It reflects some combination of redemptions and the underperformance that deep, contrarian value strategies often endure during growth-led markets. The flattening over the most recent two quarters suggests the bleed has stabilized, but it frames the Q1 2026 portfolio for what it is: a value manager that has been swimming against the tide, still patiently fishing the same unfashionable waters.

What it signals

Polaris Capital's Q1 2026 filing is a clean snapshot of orthodox global value investing in an AI-obsessed market. The firm is not chasing megacap growth; it is buying a Puerto Rican bank, Irish pharma and packaging, a specialty chemicals maker, and an energy refiner, and holding them in a broadly diversified book. The single sharpest tells this quarter are the new Eastman Chemical position and the Lantheus add — the places where a patient, contrarian manager chose to deploy fresh capital while trimming the rest.

FAQ

What is Polaris Capital Management's largest holding in Q1 2026?

Popular Inc, the largest bank in Puerto Rico, is Polaris's biggest position at 7.12% of the 13F ($87.0 million). The firm trimmed it about 5% in share terms during the quarter. No single holding exceeds about 7% of the portfolio.

What did Polaris Capital buy in Q1 2026?

Polaris opened a new 2.94% position in Eastman Chemical and added about 15% to its Lantheus Holdings stake. It trimmed several top holdings, including Popular Inc, Linde, United Therapeutics, and Smurfit WestRock.

How concentrated is Polaris Capital's portfolio?

Not very — by design. Polaris held 84 positions worth $1.22 billion in Q1 2026, with the top ten accounting for only about 44% of assets. It runs a diversified global value strategy rather than a concentrated, high-conviction book.

Why has Polaris Capital's reported 13F value fallen?

Polaris's reported U.S. assets declined from above $2.0 billion in 2024 to $1.22 billion in Q1 2026, a roughly 40% drop reflecting redemptions and the underperformance value strategies often face in growth-led markets. The figure has stabilized over the most recent two quarters.